Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CPI SHIPPING ENDOTAK 70/PRX IMPLANTABLE DEFIBRILLATOR SYSTEM

This article was originally published in The Gray Sheet

Executive Summary

CPI SHIPPING ENDOTAK 70/PRX IMPLANTABLE DEFIBRILLATOR SYSTEM following FDA approval on Aug. 5 of the Endotak 70 transvenous lead for use with the company's approved Ventak AICD automatic implantable cardioverter defibrillators. Approval of the lead makes Cardiac Pacemakers, Inc. the second company, behind Medtronic, to bring to the U.S. market a tiered-therapy defibrillator/transvenous lead combination. CPI launched the Ventak PRx implantable pacemaker/cardioverter/defibrillator in June ("The Gray Sheet" June 20, p. 18).

You may also be interested in...



Long Hot Summer For Novel Drug Reviews Forecast At US FDA

Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.

Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza

The latest drug development news and highlights from our US FDA Performance Tracker.

Epizyme’s Tazverik Gets To Market In Rare Sarcoma, Paving Way To Bigger Indications

Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.

UsernamePublicRestriction

Register

MT002675

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel